AstraZeneca's MedImmune forged a new deal with Bioasis Technologies, licensing from the Vancouver, Canada, company its brain delivery platform aimed at overcoming challenges associated with the blood-brain barrier.
To deliver large proteins past the blood-brain barrier for the treatment of Alzheimer's, researchers have developed a compound that acts as a molecular "crossing guard" for drugs to safely target brain cells and clear plaques believed to cause symptoms of the disease.
Researchers at the Karolinska Institutet in Sweden have shown that omega-3 fatty acids can cross the blood-brain barrier in a potential treatment for Alzheimer's disease.
In another successful breach of the blood-brain barrier, researchers have homed in on a nanovesicle drug capable of entering the brain and targeting tumor cells and blood vessels there.
Researchers in Finland have developed a way to penetrate the blood-brain barrier to treat schizophrenia, flooding it with high doses of the over-the-counter heartburn medicine famotidine.
Getting drugs into the brain is a bit of a holy grail, but researchers at Johns Hopkins University believe that they are a step closer with nanoparticles that can penetrate into the brain, potentially preventing recurrence of cancer after surgery by destroying any remaining tumor cells.
Researchers at the Harvard-affiliated McLean Hospital are taking a cue from the body's natural delivery method to get drugs across the blood-brain barrier.
Angiochem will work with GlaxoSmithKline ($GSK) on creating new treatments that can cross the blood-brain barrier.
Scientists are seeking health department clearance in India to begin testing a rabies treatment in humans that uses silver nanoparticles to deliver itself to the brain. The Times of India reports on
For years now, scientists have touted the enormous promise of using RNAi treatments to turn off bad genes that cause disease, but delivering the drugs effectively to their target cells, particularly